Study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurololidine-citrate and heparin catheter locks in patients treated with haemodialysis

Evaluating the need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurololidine-citrate and heparin catheter locks in patients treated with haemodialysis: An open-label, observational study with retrospective comparator groups

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN07668752

Enrollment

106

Registered

2011-04-27

Start date

2009-03-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tunnelled intravascular catheters for haemodialysis Surgery

Interventions

Interdialytic locking with taurolidine-citrate-heparin (1.35% taurolidine, 4% citrate and 500 U/ml heparin) compared to taurolidine-citrate (1.35% taurolidine, 4% citrate) and heparin 5000U/ml. Tota

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All adult haemodialysis patients requiring an internal jugular intravascular catheter for haemodialysis dialysing at single Haemodialysis Centre in NorthWest England.

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Time to first use thrombolysis for poor catheter flows 2. Time to first bacteremia	—

Secondary

Measure	Time frame
1. Incidence of gram-negative, gram-positive and staphylococcus aureus bacteraemia per 1000 catheter-days 2. Catheter survival after censoring for elective removal	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026